Search research articles
Contact Us
Filters
Showing results (101-110 of 166) with videos related to
Page
of 17
Sort By:
Cancer Biology & Therapy
|
April 7, 2022
Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis
Zibo Chen, Lin Zheng, Yulong Chen, et al.
Molecular Cancer
|
March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Nature Communications
|
November 4, 2021
The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells
Priyam Banerjee, Guan-Yu Xiao, Xiaochao Tan, et al.
Journal for Immunotherapy of Cancer
|
August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma
Sapna P Patel, Gina R Petroni, Jason Roszik, et al.
Biorxiv : the Preprint Server for Biology
|
January 31, 2024
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma
Chandrani Chattopadhyay, Jason Roszik, Rajat Bhattacharya, et al.
Cancer Research Communications
|
February 9, 2024
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer
Jonathan Goldberg, Na Qiao, Jennifer L Guerriero, et al.
Molecular Imaging and Biology
|
June 2, 2016
Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography
Amer M Najjar, Pallavi R Manuri, Simon Olivares, et al.
NPJ Precision Oncology
|
February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Cancer Discovery
|
February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma Cancers
Vivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 2018
Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition
Masanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 166) with videos related to
Sort By:
Page
of 17
Cancer Biology & Therapy
|
April 7, 2022
Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis
Zibo Chen, Lin Zheng, Yulong Chen, et al.
Molecular Cancer
|
March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Nature Communications
|
November 4, 2021
The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells
Priyam Banerjee, Guan-Yu Xiao, Xiaochao Tan, et al.
Journal for Immunotherapy of Cancer
|
August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma
Sapna P Patel, Gina R Petroni, Jason Roszik, et al.
Biorxiv : the Preprint Server for Biology
|
January 31, 2024
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma
Chandrani Chattopadhyay, Jason Roszik, Rajat Bhattacharya, et al.
Cancer Research Communications
|
February 9, 2024
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer
Jonathan Goldberg, Na Qiao, Jennifer L Guerriero, et al.
Molecular Imaging and Biology
|
June 2, 2016
Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography
Amer M Najjar, Pallavi R Manuri, Simon Olivares, et al.
NPJ Precision Oncology
|
February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Cancer Discovery
|
February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma Cancers
Vivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 2018
Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition
Masanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Page
of 17